Piper Sandler Senior Analyst David Amsellem reacts to today's Teva Innovation & Strategy Day and shares his take on the company's pipeline
He gives his thoughts on the competitiveness of Teva's TL1A, and highlights other pipeline programs that biotech investors might look at. Plus, how the company is doing transitioning its investor base from generic drug focused investors to biotech.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.